Zymeworks Inc.

NasdaqGS:ZYME Stock Report

Market Cap: US$999.4m

Zymeworks Future Growth

Future criteria checks 2/6

Zymeworks is forecast to grow earnings and revenue by 2.1% and 21.8% per annum respectively. EPS is expected to grow by 7.6% per annum. Return on equity is forecast to be -27.4% in 3 years.

Key information

2.1%

Earnings growth rate

7.6%

EPS growth rate

Biotechs earnings growth26.8%
Revenue growth rate21.8%
Future return on equity-27.4%
Analyst coverage

Good

Last updated19 Dec 2024

Recent future growth updates

Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Nov 03
Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Recent updates

Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule

Dec 19

Companies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In Growth

Dec 13
Companies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In Growth

Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 34% But Growth Is Lacking

Nov 08
Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 34% But Growth Is Lacking

Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab

Nov 04

Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Nov 03
Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook

Nov 01
Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook

Zymeworks Approaching A Moment Of Truth With Zanidatamab

Sep 27

Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week

Aug 07
Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week

Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up

Jul 26
Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up

Zymeworks: A Somewhat Complicated Story

Jul 09

Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans

Jun 12
Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans

Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business

May 03
Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business

Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data

Apr 18

Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments

Mar 05

Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion

Feb 06

Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind

Jan 31

Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M

Nov 08

Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone

Oct 26

Earnings and Revenue Growth Forecasts

NasdaqGS:ZYME - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027139-167N/A-1434
12/31/2026161-70-30-387
12/31/202584-116-86-698
12/31/202489-104-96-398
9/30/202462-114-59-55N/A
6/30/202463-113-96-91N/A
3/31/202450-126-77-73N/A
12/31/202376-119-122-118N/A
9/30/2023462205192195N/A
6/30/2023448186159165N/A
3/31/2023446173108116N/A
12/31/2022412124131144N/A
9/30/202230-224-252-234N/A
6/30/202232-237-231-212N/A
3/31/202228-240-224-207N/A
12/31/202127-212-206-192N/A
9/30/202122-211-199-190N/A
6/30/202121-223-161-155N/A
3/31/202131-194-161-155N/A
12/31/202039-181-158-151N/A
9/30/202025-215-147-140N/A
6/30/202030-173-150-135N/A
3/31/202026-163-113-98N/A
12/31/201930-145-96-82N/A
9/30/201957-64-75N/A
6/30/201951-52-23N/A
3/31/201965-291720N/A
12/31/201853-372124N/A
9/30/201874-131013N/A
6/30/201872-11N/A14N/A
3/31/201852-16N/A-5N/A
12/31/201752-11N/A0N/A
9/30/20174-55N/A-47N/A
6/30/20176-51N/A-50N/A
3/31/201711-47N/A-41N/A
12/31/201611-34N/A-35N/A
9/30/201610-30N/A-32N/A
12/31/201510-19N/A-22N/A
12/31/20142-13N/A-7N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZYME is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ZYME is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ZYME is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ZYME's revenue (21.8% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: ZYME's revenue (21.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ZYME is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 08:00
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zymeworks Inc. is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Arlinda LeeCanaccord Genuity
Yigal NochomovitzCitigroup Inc